JP2020505919A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505919A5 JP2020505919A5 JP2019539277A JP2019539277A JP2020505919A5 JP 2020505919 A5 JP2020505919 A5 JP 2020505919A5 JP 2019539277 A JP2019539277 A JP 2019539277A JP 2019539277 A JP2019539277 A JP 2019539277A JP 2020505919 A5 JP2020505919 A5 JP 2020505919A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- seq
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 21
- 102000036639 antigens Human genes 0.000 claims 21
- 108091007433 antigens Proteins 0.000 claims 21
- 239000012634 fragment Substances 0.000 claims 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 5
- 230000003247 decreasing effect Effects 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 206010065687 Bone loss Diseases 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 229920000805 Polyaspartic acid Polymers 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- 230000037182 bone density Effects 0.000 claims 1
- 230000037118 bone strength Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108010064470 polyaspartate Proteins 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023017271A JP7597836B2 (ja) | 2017-01-20 | 2023-02-08 | 骨標的抗体 |
| JP2024205967A JP2025028981A (ja) | 2017-01-20 | 2024-11-27 | 骨標的抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762448763P | 2017-01-20 | 2017-01-20 | |
| US62/448,763 | 2017-01-20 | ||
| PCT/US2018/014350 WO2018136698A2 (en) | 2017-01-20 | 2018-01-19 | Bone-targeting antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023017271A Division JP7597836B2 (ja) | 2017-01-20 | 2023-02-08 | 骨標的抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020505919A JP2020505919A (ja) | 2020-02-27 |
| JP2020505919A5 true JP2020505919A5 (enExample) | 2021-02-18 |
| JP7227138B2 JP7227138B2 (ja) | 2023-02-21 |
Family
ID=61581744
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019539277A Active JP7227138B2 (ja) | 2017-01-20 | 2018-01-19 | 骨標的抗体 |
| JP2023017271A Active JP7597836B2 (ja) | 2017-01-20 | 2023-02-08 | 骨標的抗体 |
| JP2024205967A Pending JP2025028981A (ja) | 2017-01-20 | 2024-11-27 | 骨標的抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023017271A Active JP7597836B2 (ja) | 2017-01-20 | 2023-02-08 | 骨標的抗体 |
| JP2024205967A Pending JP2025028981A (ja) | 2017-01-20 | 2024-11-27 | 骨標的抗体 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10844115B2 (enExample) |
| EP (1) | EP3571226A2 (enExample) |
| JP (3) | JP7227138B2 (enExample) |
| KR (3) | KR102613463B1 (enExample) |
| CN (2) | CN111032690B (enExample) |
| AR (1) | AR110755A1 (enExample) |
| AU (1) | AU2018210270A1 (enExample) |
| BR (1) | BR112019013986A2 (enExample) |
| CA (1) | CA3050884A1 (enExample) |
| IL (2) | IL268114B2 (enExample) |
| MX (2) | MX2019008549A (enExample) |
| MY (2) | MY207919A (enExample) |
| SG (1) | SG11201906663VA (enExample) |
| TW (3) | TWI832600B (enExample) |
| UY (1) | UY37576A (enExample) |
| WO (1) | WO2018136698A2 (enExample) |
| ZA (1) | ZA201907673B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3033614A1 (en) * | 2016-08-11 | 2018-02-15 | Precithera, Inc. | Tgf-.beta. antagonist conjugates |
| AR110755A1 (es) * | 2017-01-20 | 2019-05-02 | Genzyme Corp | Anticuerpos dirigidos a hueso |
| TW202506185A (zh) | 2017-01-20 | 2025-02-16 | 法商賽諾菲公司 | 抗TGF-β抗體及其用途 |
| EP3796941A4 (en) | 2018-05-30 | 2022-12-28 | Purdue Research Foundation | Targeting anabolic drugs for accelerated fracture repair |
| US20210155708A1 (en) * | 2018-07-10 | 2021-05-27 | Sanofi | Combination therapies against cancer targeting cd38 and tgf-beta |
| EP3884066A2 (en) * | 2018-11-19 | 2021-09-29 | Biocartis NV | Enhanced detection of low-copy-number nucleic acids in an integrated workflow |
| AU2022269615A1 (en) | 2021-05-07 | 2023-12-21 | Baylor College Of Medicine | Treatment of moderate-to-severe osteogenesis imperfecta |
| CA3226401A1 (en) * | 2021-07-20 | 2023-01-26 | William Marsh Rice University | Engineered compositions for bone-targeted therapy |
| CA3237245A1 (en) * | 2021-11-01 | 2023-05-04 | Genzyme Corporation | Treatment of osteogenesis imperfecta |
| CN115403657A (zh) * | 2022-06-23 | 2022-11-29 | 浙江大学 | 一种TGF-β3生长因子的亲和多肽及其应用 |
| WO2025184427A1 (en) * | 2024-02-27 | 2025-09-04 | Osteologic Therapeutics, Inc. | Bone-targeted antibodies and methods of use thereof |
| CN120535618B (zh) * | 2025-07-28 | 2025-09-23 | 成都大熊猫繁育研究基地 | 一种抗大熊猫cdv单克隆抗体、杂交瘤细胞株及用途 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| US4867973A (en) | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
| US5571714A (en) | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
| EP0672142B1 (en) | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| US5824655A (en) | 1995-02-15 | 1998-10-20 | The University Of Utah | Anti-transforming growth factor-β gene therapy |
| GB9601081D0 (en) | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
| DE69721548T2 (de) | 1996-02-09 | 2004-04-01 | Abbott Laboratories(Bermuda)Ltd. | HUMANE ANTIKÖRPER WELCHE AN HUMANEN TNFalpha BINDEN |
| US6455495B1 (en) | 1997-02-14 | 2002-09-24 | The Salk Institute For Biological Studies | Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents |
| EP1074563A1 (en) * | 1999-08-02 | 2001-02-07 | F. Hoffmann-La Roche Ag | Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof |
| US20030224501A1 (en) | 2000-03-17 | 2003-12-04 | Young Paul E. | Bone morphogenic protein polynucleotides, polypeptides, and antibodies |
| BR0317896A (pt) * | 2002-12-31 | 2005-12-06 | Altus Pharmaceuticals Inc | Complexos de cristais de proteìna e polìmeros iÈnicos |
| WO2004098637A1 (en) | 2003-04-30 | 2004-11-18 | Genzyme Corporation | Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency |
| EP1646655A2 (en) | 2003-07-09 | 2006-04-19 | Eli Lilly And Company | Tgf-beta1 ligands |
| CA2561686C (en) | 2004-03-31 | 2014-12-02 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
| HUE055861T2 (hu) | 2004-04-21 | 2021-12-28 | Alexion Pharma Inc | Csontbejuttató konjugátumok és azok alkalmazási módszere fehérjék csonthoz kötéséhez |
| PT3520815T (pt) | 2005-02-08 | 2022-02-02 | Genzyme Corp | Anticorpos contra tgfbeta |
| TW200714289A (en) * | 2005-02-28 | 2007-04-16 | Genentech Inc | Treatment of bone disorders |
| WO2007076391A1 (en) * | 2005-12-23 | 2007-07-05 | Eli Lilly And Company | Tgf-beta binding compositions |
| WO2008145142A1 (en) | 2007-05-31 | 2008-12-04 | Genmab A/S | Stable igg4 antibodies |
| GEP20156390B (en) | 2008-01-03 | 2015-11-10 | Scripps Research Inst | Antibody targeting through a modular recognition domain |
| US8574577B2 (en) * | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
| EP2927240A1 (en) | 2008-08-25 | 2015-10-07 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
| KR101745394B1 (ko) | 2008-12-22 | 2017-06-09 | 노보 노르디스크 에이/에스 | 조직 인자 경로 억제자에 대한 항체 |
| EP3141561B1 (en) | 2009-04-24 | 2018-09-12 | Vanderbilt University | Anti-tgf-beta induction of bone growth |
| IL300733B1 (en) | 2010-03-05 | 2025-10-01 | Univ Johns Hopkins | Compositions and methods for antibodies and fusion proteins targeted for immune modulation |
| KR20160044598A (ko) | 2011-03-29 | 2016-04-25 | 로슈 글리카트 아게 | 항체 Fc 변이체 |
| PL2699264T3 (pl) | 2011-04-20 | 2018-08-31 | Medimmune, Llc | Przeciwciała i inne cząsteczki wiążące B7-H1 i PD-1 |
| AU2012261933B2 (en) | 2011-06-03 | 2017-06-15 | Xoma Technology Ltd. | Antibodies specific for TGF-beta |
| CN116063522A (zh) | 2011-06-13 | 2023-05-05 | 美国全心医药生技股份有限公司 | 抗psgl-1抗体及其用途 |
| SG11201401605QA (en) | 2011-10-19 | 2014-09-26 | Alexion Pharma Holding | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
| US10052366B2 (en) * | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| EP2855527B1 (en) | 2012-05-31 | 2018-08-01 | Innate Pharma | Tlr3 binding agents |
| US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| EP2908913B1 (en) | 2012-10-17 | 2018-10-03 | Cedars-Sinai Medical Center | Molecular signatures of ovarian cancer |
| PL3312195T3 (pl) * | 2013-03-20 | 2020-04-30 | Genzyme Corporation | Sposoby leczenia wrodzonej łamliwości kości |
| CA2911514A1 (en) | 2013-05-06 | 2014-11-13 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
| ES2792183T3 (es) | 2013-09-13 | 2020-11-10 | Beigene Switzerland Gmbh | Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico |
| KR102630750B1 (ko) | 2013-12-17 | 2024-01-30 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| US20170216401A1 (en) * | 2014-03-17 | 2017-08-03 | Piotr Jachimczak | Combination for use in a method of treating cancer |
| CN107428825A (zh) | 2014-10-10 | 2017-12-01 | 创祐生技股份有限公司 | 治疗及/或预防肿瘤生长、侵袭及/或转移的方法 |
| MX389663B (es) | 2014-10-14 | 2025-03-20 | Novartis Ag | Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas. |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| EP3250250A4 (en) | 2015-01-30 | 2019-05-22 | President and Fellows of Harvard College | PERITUMORAL AND INTRATUMORAL MATERIALS FOR CANCER THERAPY |
| TWI733661B (zh) | 2015-03-04 | 2021-07-21 | 美商健臻公司 | 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體 |
| JP6901400B2 (ja) | 2015-04-03 | 2021-07-14 | ゾーマ テクノロジー リミテッド | ＴＧＦ−β及びＰＤ−１の阻害物質を使用する癌の治療法 |
| NZ735820A (en) | 2015-04-17 | 2025-02-28 | Bristol Myers Squibb Co | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
| WO2017011773A2 (en) * | 2015-07-15 | 2017-01-19 | Modernatx, Inc. | Codon-optimized nucleic acids encoding antibodies |
| EP3344660B1 (en) * | 2015-08-31 | 2025-03-05 | National Research Council of Canada | Tgf-beta-receptor ectodomain fusion molecules and uses thereof |
| CA3033614A1 (en) | 2016-08-11 | 2018-02-15 | Precithera, Inc. | Tgf-.beta. antagonist conjugates |
| AR110755A1 (es) | 2017-01-20 | 2019-05-02 | Genzyme Corp | Anticuerpos dirigidos a hueso |
| TW202506185A (zh) | 2017-01-20 | 2025-02-16 | 法商賽諾菲公司 | 抗TGF-β抗體及其用途 |
-
2018
- 2018-01-18 AR ARP180100119A patent/AR110755A1/es unknown
- 2018-01-18 TW TW111146907A patent/TWI832600B/zh active
- 2018-01-18 TW TW113101673A patent/TW202421659A/zh unknown
- 2018-01-18 TW TW107101790A patent/TWI788321B/zh active
- 2018-01-19 EP EP18709437.0A patent/EP3571226A2/en active Pending
- 2018-01-19 CN CN201880007783.2A patent/CN111032690B/zh active Active
- 2018-01-19 MY MYPI2022003998A patent/MY207919A/en unknown
- 2018-01-19 US US15/875,125 patent/US10844115B2/en active Active
- 2018-01-19 IL IL268114A patent/IL268114B2/en unknown
- 2018-01-19 CN CN202410319667.1A patent/CN118121696A/zh active Pending
- 2018-01-19 KR KR1020197024021A patent/KR102613463B1/ko active Active
- 2018-01-19 SG SG11201906663VA patent/SG11201906663VA/en unknown
- 2018-01-19 BR BR112019013986-9A patent/BR112019013986A2/pt not_active IP Right Cessation
- 2018-01-19 UY UY0001037576A patent/UY37576A/es not_active Application Discontinuation
- 2018-01-19 JP JP2019539277A patent/JP7227138B2/ja active Active
- 2018-01-19 AU AU2018210270A patent/AU2018210270A1/en not_active Abandoned
- 2018-01-19 WO PCT/US2018/014350 patent/WO2018136698A2/en not_active Ceased
- 2018-01-19 KR KR1020237042558A patent/KR102755284B1/ko active Active
- 2018-01-19 IL IL317592A patent/IL317592A/en unknown
- 2018-01-19 CA CA3050884A patent/CA3050884A1/en active Pending
- 2018-01-19 MX MX2019008549A patent/MX2019008549A/es unknown
- 2018-01-19 KR KR1020257000987A patent/KR20250012197A/ko active Pending
- 2018-01-19 MY MYPI2019006821A patent/MY194819A/en unknown
-
2019
- 2019-07-17 MX MX2022008073A patent/MX2022008073A/es unknown
- 2019-11-20 ZA ZA2019/07673A patent/ZA201907673B/en unknown
-
2020
- 2020-10-23 US US17/079,285 patent/US12098194B2/en active Active
-
2023
- 2023-02-08 JP JP2023017271A patent/JP7597836B2/ja active Active
-
2024
- 2024-08-13 US US18/802,674 patent/US20250074975A1/en active Pending
- 2024-11-27 JP JP2024205967A patent/JP2025028981A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020505919A5 (enExample) | ||
| JP2023058590A5 (enExample) | ||
| JP2020517287A5 (enExample) | ||
| CN113354729B (zh) | 一种抗新型冠状病毒的单克隆抗体及其应用 | |
| JP2018502050A5 (enExample) | ||
| JP2020533311A5 (ja) | ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質 | |
| KR20180012860A (ko) | 이종 이량체 다중 특이적 항체 포맷 | |
| CN115605511A (zh) | 抗tigit的抗体、其制备方法和应用 | |
| CN111454357A (zh) | 一种含有抗体的肿瘤治疗剂的开发和应用 | |
| JP2021159081A5 (enExample) | ||
| CN113354730B (zh) | 一种抗新型冠状病毒的单克隆抗体及其应用 | |
| JP2011526249A5 (enExample) | ||
| CN113150156B (zh) | 抗tigit抗体及其用途 | |
| RU2019134462A (ru) | Антитела, связывающиеся с steap-1 | |
| CN110869390A (zh) | 抗pd-l1抗体及其用途 | |
| JP2010509931A5 (enExample) | ||
| JP2020502233A5 (enExample) | ||
| JP2019505565A5 (enExample) | ||
| AU2019277546A1 (en) | Nav1.7 monoclonal antibody | |
| JP2016529213A5 (enExample) | ||
| RU2019104896A (ru) | Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и способы их использования | |
| JPWO2022094299A5 (enExample) | ||
| JP2008532559A5 (enExample) | ||
| JPWO2021007260A5 (enExample) | ||
| JPWO2021224913A5 (enExample) |